Alivus Life Sciences Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 4,30,756 shares,. Its Average Traded Price (ATP) is ₹1466.87, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 2445 @ ₹1444.70.
Alivus Life Sciences has an upper circuit limit of ₹1737.30 and a lower circuit limit of ₹1158.30. The total value traded stands at ₹63.19 CR, and the delivery percentage for the day is 57.07%.
The stock is currently traded with a market lot size of 1. Alivus Life Sciences also offers a dividend yield of 0%.
Alivus Life Sciences Share Price Chart
Alivus Life Sciences Share Key Metrics
Volume
4.31 L
Market Cap
17736.79 CR
LTQ@LTP
2445@1444.70
ATP
1466.87
Var Margin
16.95 %
Circuit Range
1158.3-1737.3
Delivery %
57.07 %
Value
63.19 CR
ASM/GSM
No
Market Lot
1
Alivus Life Sciences Resistance and Support
Pivot 1451.3
Resistance
First Resistance
1467.2
Second Resistance
1486.6
Third Resistance
1502.5
Support
First Support
1431.9
Second Support
1416
Third Support
1396.6
Alivus Life Sciences Shareholding Pattern
View More- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Alivus Life Sciences Corporate Actions
| Date | Agenda |
|---|---|
| 2026-10-29 | Quarterly Results |
| 2026-07-30 | Quarterly Results |
| 2026-05-14 | Audited Results & Final Dividend |
| 2026-01-22 | Quarterly Results |
| 2025-11-06 | Quarterly Results |
| 2025-08-01 | Quarterly Results |
| 2025-05-15 | Audited Results & Final Dividend |
| 2025-01-23 | Quarterly Results |
| 2024-10-24 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2026-09-01 | 2026-09-01 | View More |
Alivus Life Sciences News
Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Alivus Life Sciences has acquired a 65.01% stake in IQGEN-X Pharma Private Limited, initiating the closure of its share purchase agreement. IQGEN-X has now become a subsidiary, with the remaining stake for the planned 76% acquisition to be completed soon.
Nov 11 2026 18:28:37
Alivus Life Sciences Ltd - 543322 - Announcement Under Regulation 30 - Updates
Alivus Life Sciences executed a Shareholders' Agreement with IQGEN-X Pharma and its continuing existing shareholders. The agreement grants Alivus majority board control (2 of 3 directors) and an option to acquire the remaining 24% stake at the end of 5 years.
Nov 11 2026 16:52:47
Alivus Life Sciences Ltd - 543322 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Promoter Nirma Limited sold 36.8 lakh shares (2.99% stake) via open market on 6 Nov 2026. Post-transaction, the total promoter holding has decreased from 74.73% to 71.74%.
Nov 07 2026 15:18:14
Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alivus Life Sciences reported a 51.3% YoY increase in Q2 FY27 net profit to Rs.196.8 cr on a 16% YoY growth in revenue to Rs.682 cr. The strong performance was driven by a favorable product mix, new launches, and benefits of operating leverage.
Oct 29 2026 19:33:30
Alivus Life Sciences Ltd - 543322 - Board Meeting Outcome for Unaudited Financial Results For The Second Quarter And Half Year Ended September 30, 2026.
Alivus Life Sciences reported Q2 FY26 revenue of ₹682 crores (up 16% YoY) and net profit of ₹197 crores (up 51% YoY). The company also incorporated a new wholly-owned subsidiary in Sao Paulo, Brazil.
Oct 29 2026 19:29:08
Alivus Life Sciences Ltd - 543322 - Closure of Trading Window
Alivus Life Sciences has scheduled a board meeting on October 29, 2026. The board will consider and approve the financial results for Q2 FY27.
Oct 21 2026 17:17:01
Alivus Life Sciences Ltd - 543322 - Board Meeting Intimation for Inter-Alia, Considering And Approving Unaudited Financial Results Of The Company For The Quarter And Half Year Ended 30Th September, 2026.
Alivus Life Sciences' board will meet on October 29, 2026, for financial results. The results will cover the quarter and half-year ended September 30, 2026.
Oct 21 2026 17:09:13
Alivus Life Sciences Management
| Name | Position |
|---|---|
| Rudalf Corriea | Company Secretary & Compliance Officer |
| Hiren K Patel | Chairman |
Alivus Life Sciences Similar Stocks
Jubilant Pharmova Ltd.
933.60
-20.90 (2.19%)
Marksans Pharma Ltd.
294.50
-11.60 (3.79%)
CORONA Remedies Ltd.
2256.20
-19.40 (0.85%)
Sudeep Pharma Ltd.
1202.20
-15.30 (1.26%)
Rainbow Children's Medicare Ltd.
1258.00
-12.40 (0.98%)
Concord Biotech Ltd.
561.00
6.20 (1.12%)
Metropolis Healthcare Ltd.
564.30
-2.70 (0.48%)
Akums Drugs & Pharmaceuticals Ltd.
716.15
-0.45 (0.06%)
Sanofi Consumer Healthcare India Ltd.
3532.30
-0.10 (0.00%)
Park Medi World Ltd.
238.04
-1.97 (0.82%)
Alivus Life Sciences FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in ALIVUS
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC